Navigation Links
Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
Date:10/23/2008

PARIS, October 23 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces positive results from its Phase II clinical trial evaluating NXL103 in the treatment of community acquired pneumonia (CAP). NXL103 is a novel oral streptogramin antibiotic that has potent in vitro activity against certain Gram positive bacteria including methicillin resistant Staphylococcus aureus (MRSA) as well as the important respiratory pathogens including penicillin, macrolide and quinolone resistant strains.

The NXL103 Phase II study was a double-blind, multinational, randomized, comparative study that evaluated this novel oral antibacterial as a treatment for mild to moderate CAP. The study recruited 300 adult patients in 9 countries in both the Northern and Southern hemispheres. Patients were randomised (1:1:1) to three treatment arms: 500mg of NXL103 twice a day, 600mg NXL103 twice a day or 1,000 mg of amoxicillin three times a day for 7 days. The key endpoints of the study were the clinical outcome in the clinically evaluable population at the early follow-up visit (7 to 14 days post-therapy) and safety. In this study, both doses of NXL103 were effective, with clinical response rates similar to those seen in the amoxicillin group. For the primary efficacy analysis, response rates were 91.4% in the 500mg NXL103 group; 94.7% in the 600mg NXL103 group; and 88.5% in the amoxicillin group. NXL103 was generally well tolerated with the most frequent adverse events related to gastrointestinal intolerance. There were no serious drug-related adverse events reported in the study.

The complete results from this Phase II trial will be published in the first half of 2009.

NXL103 has a spectrum of activity that indicates it has the potential to be effective in the treatment of skin and skin structure infections, includi
'/>"/>

SOURCE Novexel
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio
2. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
3. Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien(TM) Study
4. BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test
5. Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
6. MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
7. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
8. Nutrition 21 Reports That National Toxicology Program Studies Support the Safety of Chromium Picolinate
9. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
10. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
11. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Calif. , June 1, 2015   ... a biopharmaceutical company leading the discovery and development ... Kleanthis G. Xanthopoulos , Ph.D. has resigned ... a member of Regulus, Board of Directors, effective ... industry.  Paul Grint, M.D., who previously served as ...
(Date:6/1/2015)... 1, 2015 About Pressure ... large area and improve the quality life of patients ... devices play a significant role in inhibiting the growth ... need to turn or rotate an immobile patient by ... mattresses overlay, and specialty beds. These devices have the ...
(Date:6/1/2015)... , June 1, 2015 NEOVIA ... company engaged in the development and commercialization of ... that it has met with the U.S. Food ... the filing of an Investigational New Drug (IND) ... As a result of the meeting, Neovia has ...
Breaking Medicine Technology:Regulus' Kleanthis G. Xanthopoulos, Ph.D., to Step Down as President and Chief Executive Officer 2Regulus' Kleanthis G. Xanthopoulos, Ph.D., to Step Down as President and Chief Executive Officer 3Regulus' Kleanthis G. Xanthopoulos, Ph.D., to Step Down as President and Chief Executive Officer 4Global Pressure Relief Devices Market 2015-2019 2Global Pressure Relief Devices Market 2015-2019 3Neovia Oncology Announces First IND Meeting 2
... Therapeutics (NYSE Amex: CXM ) today ... a topically applied formulated collagen wound management gel ... factor (PDGF) locally at the wound site.  This ... essential role in the wound healing process. ...
... Prime Therapeutics (Prime), a thought leader in ... awarded full Pharmacy Benefit Management (PBM) accreditation from ... that establishes quality standards for the health care ... URAC accreditation in 2007, and has also achieved ...
Cached Medicine Technology:Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process 2Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process 3Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process 4Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process 5Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process 6Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process 7Prime Therapeutics Announces URAC Accreditation 2
(Date:6/2/2015)... 02, 2015 Glidewell Laboratories, industry-leading ... today that the new issue of Chairside® magazine, ... and online. The digital edition of the latest ... past issues of the dental laboratory’s magazine, can ... smartphone platforms by visiting http://www.chairsidemagazine.com . , ...
(Date:6/2/2015)... 02, 2015 The Non-GMO Project ... products made according to rigorous best practices for ... produced in compliance with the Non-GMO Project Standard ... risk ingredients, facility inspections and an annual audit ... avoidance. , “Savoury Systems is and has always ...
(Date:6/2/2015)... 02, 2015 Mercy Health (formerly Catholic ... and Kentucky – has devoted the seventh of its ... skin cancer prevention. One in five Americans will get ... Health’s YouTube channel, a Mercy Health expert addresses these ... main causes of skin cancer? ,     What are ...
(Date:6/2/2015)... June 02, 2015 The Radiosurgery ... study from the RSSearch® Patient Registry evaluating the ... radiotherapy (SBRT) for the treatment of centrally located ... metastases. , The study, published in the ... ), included 111 patients with 114 centrally located ...
(Date:6/2/2015)... Dallas, TX (PRWEB) June 02, 2015 FDA ... to qualified Diet Doc patients after a satisfactory doctor consultation. ... on the market for several years and has the longest ... Working to block the enzyme that breaks down fats in ... diverting them through the intestinal system to be excreted through ...
Breaking Medicine News(10 mins):Health News:Glidewell Laboratories Releases New Issue of Restorative Dentistry Magazine Chairside in Print and Online 2Health News:Glidewell Laboratories Releases New Issue of Restorative Dentistry Magazine Chairside in Print and Online 3Health News:Savoury Systems International Receives Non-GMO Project Verification Continuing its Commitment to Provide Customers with Clean Label Ingredients 2Health News:Video provides helpful information about skin cancer prevention 2Health News:New Study from RSSearch® Patient Registry Highlights Treatment Patterns and Clinical Outcomes of Stereotactic Radiosurgery for Central Lung Tumors 2Health News:New Study from RSSearch® Patient Registry Highlights Treatment Patterns and Clinical Outcomes of Stereotactic Radiosurgery for Central Lung Tumors 3Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 2Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 3Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 4
... technology that was developed for an aerospace high-speed ... device for heart failure patients.(Logo: http://www.newscom.com/cgi-bin/prnh/20081007/38461LOGO )NASA,s ... advanced aerospace resin, named Langley Research Center,s Soluble ... to chemicals, and withstands extreme hot and cold ...
... Senate recently introduced legislation that would increase access to ... need for a physician,s referral or certification of the ... access is authorized, says the American Physical Therapy Association ... Therapists Act (S 950), introduced by Senators Blanche Lincoln ...
... Increased Case Volume Continue to Drive Revenue GrowthALISO VIEJO, Calif., ... (Nasdaq: CLRT ), a premier ... and the pharmaceutical industry, today reported $22.4 million in revenue ... increase as compared with $15.9 million for the same period ...
... a.m. Central Daylight Time. HOUSTON, May 6 Service Corporation International (NYSE: SCI ), ... Our consolidated financial statements can be found at the end of this press release. ... ... ...
... May 6 The Generic Animal Drug Alliance ... animal health industry interests, says that the recent ... illustrates the potential safety issues surrounding compounded drugs ... Food and Drug Administration (FDA) approved animal generic ...
... of the nation,s leading cardioelectrophysiologists, has joined The Mount Sinai Medical ... ... York, NY (Vocus)-- Vivek Y. Reddy, M.D., one of the nation,s ... as Director of Electrophysiology Laboratories. His appointment becomes effective July ...
Cached Medicine News:Health News:Cardiac Patients Take NASA Super Plastic to Heart 2Health News:Cardiac Patients Take NASA Super Plastic to Heart 3Health News:Senate Introduces Legislation to Increase Access to Physical Therapist Services 2Health News:Clarient Reports 41% Revenue Increase for First Quarter 2009 2Health News:Clarient Reports 41% Revenue Increase for First Quarter 2009 3Health News:Clarient Reports 41% Revenue Increase for First Quarter 2009 4Health News:Clarient Reports 41% Revenue Increase for First Quarter 2009 5Health News:Clarient Reports 41% Revenue Increase for First Quarter 2009 6Health News:Clarient Reports 41% Revenue Increase for First Quarter 2009 7Health News:Clarient Reports 41% Revenue Increase for First Quarter 2009 8Health News:Clarient Reports 41% Revenue Increase for First Quarter 2009 9Health News:Service Corporation International Announces First Quarter 2009 Financial Results 2Health News:Service Corporation International Announces First Quarter 2009 Financial Results 3Health News:Service Corporation International Announces First Quarter 2009 Financial Results 4Health News:Service Corporation International Announces First Quarter 2009 Financial Results 5Health News:Service Corporation International Announces First Quarter 2009 Financial Results 6Health News:Service Corporation International Announces First Quarter 2009 Financial Results 7Health News:Service Corporation International Announces First Quarter 2009 Financial Results 8Health News:Service Corporation International Announces First Quarter 2009 Financial Results 9Health News:Service Corporation International Announces First Quarter 2009 Financial Results 10Health News:Service Corporation International Announces First Quarter 2009 Financial Results 11Health News:Service Corporation International Announces First Quarter 2009 Financial Results 12Health News:Service Corporation International Announces First Quarter 2009 Financial Results 13Health News:Service Corporation International Announces First Quarter 2009 Financial Results 14Health News:Service Corporation International Announces First Quarter 2009 Financial Results 15Health News:Service Corporation International Announces First Quarter 2009 Financial Results 16Health News:Service Corporation International Announces First Quarter 2009 Financial Results 17Health News:Service Corporation International Announces First Quarter 2009 Financial Results 18Health News:Service Corporation International Announces First Quarter 2009 Financial Results 19Health News:Service Corporation International Announces First Quarter 2009 Financial Results 20Health News:Service Corporation International Announces First Quarter 2009 Financial Results 21Health News:Service Corporation International Announces First Quarter 2009 Financial Results 22Health News:GADA Points to Safety of FDA Approved Generics in Wake of Wellington Polo Horse Deaths from Compounded Drugs 2Health News:Vivek Y. Reddy, M.D., Joins The Mount Sinai Medical Center as Director of Electrophysiology Laboratories 2Health News:Vivek Y. Reddy, M.D., Joins The Mount Sinai Medical Center as Director of Electrophysiology Laboratories 3
...
...
...
Open blade speculum designed for both temporal and superior approach ocular surgery. Thumb screw adjusting mechanism. Manufactured in titanium....
Medicine Products: